Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy

Cell Reports(2024)10.1016/j.celrep.2024.114141Source: DataRank Database

Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy is a research paper published in Cell Reports (2024). On theSindex it has a DataRank of 0. It has been cited 23 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access23 citations

Download PDF

Cite:

Linked data & code

geo gen pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)OA: goldTopics (50)IDs (PubMed, PMC)Annotations (3)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Brendan Horton ORCID,Emily F. Higgs ORCID,Ken Hatogai ORCID,Anna Martinez ORCID,Jason W. Shapiro ORCID

Live enrichment

PubMed:38656869 PMC:PMC11229087

NICHD NIH HHS

Grant: T32 HD007009

NCI NIH HHS

Grant: R35 CA210098

NCI NIH HHS

Grant: T32 CA009594

NIAID NIH HHS

Grant: T32 AI007090

National Institutes of Health

Grant: 5R35CA210098-07

Overcoming resistance to anti-PD1 immunotherapy

NIH

goldLicense: CC BY NC

publisherhttp://www.cell.com/article/S2211124724004698/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2211124724004698?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2211124724004698?httpAccept=text/plain

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11229087/pdf/nihms-2000770.pdf

repositoryhttp://knowledge.uchicago.edu/record/11579

Fields of Study

0301 basic medicine03 medical and health sciences0303 health sciences

MeSH Terms

Dendritic CellsCD8-Positive T-LymphocytesCell Line, TumorAnimalsMice, Inbred C57BLHumansMiceRepressor ProteinsSignal TransductionBasic-Leucine Zipper Transcription Factors4-1BB LigandTumor MicroenvironmentProgrammed Cell Death 1 ReceptorTumor Necrosis Factor Receptor Superfamily, Member 9B7-H1 AntigenImmune Checkpoint Inhibitors

Keywords

Immunotherapy4-1BBL4-1BBCd8(+) T CellsPd-1/pd-l1 BlockadeSpatial TranscriptomicsImmunotherapy EfficacyCp: ImmunologyCp: CancerBatf3-lineage Dendritic CellsDc1sQH301-705.5Programmed Cell Death 1 ReceptorCD8-Positive T-LymphocytesCD8+ T cellsArticleB7-H1 AntigenMiceTumor Necrosis Factor Receptor Superfamily, Member 9Cell Line, TumorTumor MicroenvironmentAnimalsHumansBiology (General)Immune Checkpoint InhibitorsDendritic CellsMice, Inbred C57BLRepressor Proteins4-1BB LigandBasic-Leucine Zipper Transcription FactorsSignal Transduction

Sustainable Development Goals

SDG 3: 3. Good health

Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy

FAIR Checklist

Authors (10)

Funding (6 grants)

Open Access

Topics

Annotations (Europe PMC)